GET A VALUABLE CERTIFICATE FOR JOB MARKET


ACADEMIC RECOGNITION OF 3 OR 6 CREDITS


DESIGNED FOR EXPERTS BY EXPERTS


ADVANCED QUANTITATIVE BENEFIT-RISK ASSESSMENT METHODS IN DECISION MAKING ON MEDICINES


OBJECTIVES



Decision making on medicines informed by quantitative benefit-risk assessment may differ depending on the perspective of the decision maker and the phase of drug development.

This module will address the decision-making on medicines by different stakeholders and how to apply advanced benefit-risk assessment tools in this process.

Applied decision making, individualized benefit-risk assessment, real life data, graphical representation

 

MODULE PARTS



  1. Multi-criteria decision analysis
  2. Conjoint analysis
  3. Personalized benefit-risk assessment

 

TRAINER TEAM



Coordinator: Dr Jet Van Der Zijden (from Utrecht Universiteit)

Expert(s): Prof Olaf Klungel, Dr Rianne Van Den Ham, Dr Tjeerd Van Staa, Dr Rob Heerdink, Dr Anke Hilse Maitland - Van Der Zee, Dr Rob Hermans (from Utrecht Universiteit), Dr George Quartey (from F. Hoffmann-La Roche Ltd), Dr Filip Mussen (from Janssen Pharmaceutica NV).

Advanced level
75 h workload over 3 months (3 ECTS credits)
Key dates
Course calendar
Certificate award
or included in Master Year 2 or PhD programme
English language
Online based learning
Student: 1,500 €
Professional: 3,000 €
  Savings could be offered under eligibility conditions.

Applications currently closed

Application to this training will be available
from June 18th, 2018 to March 24th, 2019.
Thanks for applying during this period.

Contact the Eu2P Central Office

Applications will open on June 18th, 2018. Please contact the Eu2P Central Office for information.

Or include this module in your training curriculum choices...

Master Year 2 PhD



Confused? Read the FAQs...

NEED TO TALK TO US?

+33 5 47 30 42 69

Monday-Friday / 9.00am-6.00pm CET

 

Supported By

IMI logo EU logo efpia logo

Created By

Eu2P Partners